Published in AIDS Weekly, May 13th, 1996
Under the terms of the agreement, both companies commit a team of research scientists to discover treatments for hepatitis C and HIV. The agreement, which calls for shared research, development and commercialization, is for a period of five years, with a review after three years.
"Oncogene Science is at the forefront of drug lead discovery and is a leader in high throughput...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.